Singapore, May 7 -- BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, has announced the signing of a binding Heads of Terms agreement with Wellington Zhaotai Therapies, under which BioOra secures global rights to develop and commercialise Wellington Zhaotai's novel third-generation anti-CD19 CAR T-cell therapy for the treatment of multiple conditions (WZTL-002), including haematological malignancies and auto-immune diseases.

BioOra has combined the unique CAR-T asset developed by Wellington Zhaotai, with BioOra's manufacturing and commercialisation expertise to deliver Atla-cel, an autologous CAR T-cell product incorporating patented co-stimulatory domains designed to deliver robus...